XML 39 R30.htm IDEA: XBRL DOCUMENT
v3.22.2

MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Revenues Recognized under Agreement (Detail) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended
--- | --- | ---
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |
Revenues | $ 29,378 | $ 27,872 | $ 57,609 | $ 54,152
Novartis Institutes for BioMedical Research, Inc. |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |
Revenues | 10,928 | 9,581 | 19,823 | 17,442
Novartis Institutes for BioMedical Research, Inc. | Recognition of upfront fee |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |
Revenues | 8,622 | 7,559 | 15,640 | 13,759
Novartis Institutes for BioMedical Research, Inc. | Research services |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |
Revenues | 2,306 | 2,022 | 4,183 | 3,683
Biogen MA, Inc. |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |
Revenues | 10,052 | 10,767 | 21,245 | 21,217
Biogen MA, Inc. | Recognition of upfront fee |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |
Revenues | 7,306 | 7,306 | 14,612 | 14,612
Biogen MA, Inc. | Research services |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |
Revenues | 2,746 | 3,461 | 6,633 | 6,605
Kite Pharma, Inc. |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |
Revenues | 6,334 | 6,324 | 12,642 | 12,612
Kite Pharma, Inc. | Recognition of upfront fee |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |
Revenues | 6,227 | 6,227 | 12,386 | 12,386
Kite Pharma, Inc. | Research services |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |
Revenues | 107 | 97 | 256 | 226
Sanofi |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |
Revenues | 1,761 | 957 | 3,260 | 2,017
Sanofi | Recognition of upfront fee |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |
Revenues | 366 | 206 | 677 | 433
Sanofi | Research services |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |
Revenues | 1,148 | 613 | 2,126 | 1,292
Sanofi | Milestone achievement |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |
Revenues | $ 247 | $ 138 | $ 457 | $ 292

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=sgmo_ResearchServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_SanofiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=sgmo_MilestoneAchievementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |